Localized CD47 blockade enhances immunotherapy for murine melanoma
Jessica R Ingram,Olga S Blomberg,Jonathan T Sockolosky,Lestat Ali,Florian I Schmidt,Novalia Pishesha,Camilo Espinosa,Stephanie K Dougan,K Christopher Garcia,Hidde L Ploegh,Michael Dougan,Jessica R. Ingram,Olga S. Blomberg,Jonathan T. Sockolosky,Florian I. Schmidt,Stephanie K. Dougan,K. Christopher Garcia,Hidde L. Ploegh
DOI: https://doi.org/10.1073/pnas.1710776114
IF: 11.1
2017-09-05
Proceedings of the National Academy of Sciences
Abstract:Significance CD47 is a broadly expressed membrane-associated innate immune regulator that acts as a ligand of signal regulatory protein alpha (SIRPα) on antigen-presenting cells to inhibit phagocytosis. In xenograft models, inhibitors of the CD47–SIRPα interaction selectively target tumor-expressed CD47 and improve antibody responses to tumors by enhancing antibody-dependent cellular phagocytosis. In syngeneic settings, however, broad expression of CD47 on cells of the hematopoietic lineage creates a formidable antigen sink and increases toxicity. We find that optimal synergy between anti-CD47 antibodies and several immune therapies, including anti–CTLA-4, requires near-complete blockade of CD47 in the tumor microenvironment. Thus, novel strategies to deliver localized CD47 blockade to tumors may be particularly valuable for immune therapy.
multidisciplinary sciences